These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 15597134)

  • 21. Side effects associated with psychotropic medications in patients with bipolar disorder: evidence from two independent samples.
    Serretti A; Chiesa A; Calati R; Fabbri C; Sentissi O; De Ronchi D; Mendlewicz J; Souery D
    J Psychopharmacol; 2013 Jul; 27(7):616-28. PubMed ID: 23616438
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Toward a biaxial model of "bipolar" affective disorders: spectrum phenotypes as the products of neuroelectrical and neurochemical alterations.
    Askland K; Parsons M
    J Affect Disord; 2006 Aug; 94(1-3):15-33. PubMed ID: 16725206
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pediatric bipolar disorder: evidence-based psychopharmacological treatments.
    Hamrin V; Pachler M
    J Child Adolesc Psychiatr Nurs; 2007 Feb; 20(1):40-58. PubMed ID: 17284237
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synaptic, intracellular, and neuroprotective mechanisms of anticonvulsants: are they relevant for the treatment and course of bipolar disorders?
    Li X; Ketter TA; Frye MA
    J Affect Disord; 2002 May; 69(1-3):1-14. PubMed ID: 12103447
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is the combination of a mood stabilizer plus an antipsychotic more effective than mono-therapies in long-term treatment of bipolar disorder? A systematic review.
    Buoli M; Serati M; Altamura AC
    J Affect Disord; 2014 Jan; 152-154():12-8. PubMed ID: 24041717
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Quetiapin in bipolar disorders].
    Sümegi A
    Neuropsychopharmacol Hung; 2008 Dec; 10(5):281-91. PubMed ID: 19419014
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neurobiological bases of quetiapine antidepresant effect in the bipolar disorder.
    Prieto E; Micó JA; Meana JJ; Majadas S
    Actas Esp Psiquiatr; 2010; 38(1):22-32. PubMed ID: 20931407
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacological Treatment Patterns at Study Entry for the First 500 STEP-BD Participants.
    Ghaemi SN; Hsu DJ; Thase ME; Wisniewski SR; Nierenberg AA; Miyahara S; Sachs G
    Psychiatr Serv; 2006 May; 57(5):660-5. PubMed ID: 16675760
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Allopurinol for mania: a randomized trial of allopurinol versus placebo as add-on treatment to mood stabilizers and/or antipsychotic agents in manic patients with bipolar disorder.
    Weiser M; Burshtein S; Gershon AA; Marian G; Vlad N; Grecu IG; Tocari E; Tiugan A; Hotineanu M; Davis JM
    Bipolar Disord; 2014 Jun; 16(4):441-7. PubMed ID: 24712840
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emerging experimental therapeutics for bipolar disorder: clues from the molecular pathophysiology.
    Quiroz JA; Singh J; Gould TD; Denicoff KD; Zarate CA; Manji HK
    Mol Psychiatry; 2004 Aug; 9(8):756-76. PubMed ID: 15136795
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neural circuits underlying the pathophysiology of mood disorders.
    Price JL; Drevets WC
    Trends Cogn Sci; 2012 Jan; 16(1):61-71. PubMed ID: 22197477
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modulation of CNS signal transduction pathways and gene expression by mood-stabilizing agents: therapeutic implications.
    Manji HK; Bebchuk JM; Moore GJ; Glitz D; Hasanat KA; Chen G
    J Clin Psychiatry; 1999; 60 Suppl 2():27-39; discussion 40-1, 113-6. PubMed ID: 10073385
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Does recent mania affect response to antidepressants in bipolar disorder? A re-analysis of STEP-BD data.
    Mousavi Z; Johnson S; Li D
    J Affect Disord; 2018 Aug; 236():136-139. PubMed ID: 29734096
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regional cerebral glucose metabolic abnormalities in bipolar II depression.
    Mah L; Zarate CA; Singh J; Duan YF; Luckenbaugh DA; Manji HK; Drevets WC
    Biol Psychiatry; 2007 Mar; 61(6):765-75. PubMed ID: 17027930
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The use of mood stabilizers and atypical antipsychotics in children and adolescents with bipolar disorders.
    Kowatch RA; DelBello MP
    CNS Spectr; 2003 Apr; 8(4):273-80. PubMed ID: 12679742
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antipsychotic switching in bipolar disorders: a systematic review.
    Grande I; Bernardo M; Bobes J; Saiz-Ruiz J; Álamo C; Vieta E
    Int J Neuropsychopharmacol; 2014 Mar; 17(3):497-507. PubMed ID: 24139622
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictors of adherence to psychopharmacological and psychosocial treatment in bipolar I or II disorders - an 18-month prospective study.
    Arvilommi P; Suominen K; Mantere O; Leppämäki S; Valtonen H; Isometsä E
    J Affect Disord; 2014 Feb; 155():110-7. PubMed ID: 24262639
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The extracellular signal-regulated kinase pathway: an emerging promising target for mood stabilizers.
    Chen G; Manji HK
    Curr Opin Psychiatry; 2006 May; 19(3):313-23. PubMed ID: 16612219
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers.
    Gould TD; Quiroz JA; Singh J; Zarate CA; Manji HK
    Mol Psychiatry; 2004 Aug; 9(8):734-55. PubMed ID: 15136794
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Excitatory and inhibitory synaptic dysfunction in mania: an emerging hypothesis from animal model studies.
    Lee Y; Zhang Y; Kim S; Han K
    Exp Mol Med; 2018 Apr; 50(4):1-11. PubMed ID: 29628501
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.